Progress in drug treatment of tuberculosis complicated diabetes

doi:10.19871/j.cnki.xfcrbzz.2023.02.016

Abstract

Abstract: Lifestyle changes have brought about a pandemic of diabetes. As an ancient disease, tuberculosis also has an increasing trend. The trend of co morbidity of tuberculosis and diabetes is increasingly obvious. Tuberculosis and diabetes interact with each other, promote each other, aggravate the condition of infected persons and make their clinical diagnosis and treatment complicated. This review focuses on the main points of medical nutrition therapy for tuberculosis complicated diabetes, the special features of anti-tuberculosis therapy for diabetic patients, the types of antidiabetic drugs for patients with tuberculosis complicated diabetes and their relationship with anti-tuberculosis therapy, as a way to improve the effectiveness of drug therapy for tuberculosis complicated diabetes.

Key words: Diabetes, Tuberculosis, Coexistence of tuberculosis and diabetes mellitus, Drug treatment

CLC Number:

R516
R587.1

Xu Xinyue, Zhao Xiaolong. Progress in drug treatment of tuberculosis complicated diabetes[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(2): 74-77.

References

[1] THE LANCET PUBLIC H. Renewing the fight to end tuberculosis[J]. Lancet Public Health, 2021,6(5): e260.
[2] CHAKAYA J, KHAN M, NTOUMI F, et al. Global Tuberculosis Report2020 - Reflections on the Global TB burden, treatment and prevention efforts[J]. Int J Infect Dis, 2021,113 Suppl 1(Suppl 1):S7-S12.
[3] ANTONIO ARQUES V, FRANCHNADAL J, CAYLA JA.Diabetes and tuberculosis: A syndemic complicated by COVID-19[J]. Med Clin (Engl Ed), 2021,157(6):288-293.
[4] SALIFU RS, HLONGWA M, HLONGWANA K.Implementation of the WHO's collaborative framework for the management of tuberculosis and diabetes: a scoping review[J]. BMJ Open, 2021,11(11): e047342.
[5] LU P, ZHANG Y, LIU Q, et al.Association of BMI, diabetes, and risk of tuberculosis: a population-based prospective cohort[J]. Int J Infect Dis, 2021,109:168-173.
[6] 中华医学会结核病学分会重症专业委员会. 结核病营养治疗专家共识[J]. 中华结核和呼吸杂志, 2020,43(1):17-26.
[7] WHO Guidelines Approved by the Guidelines Review Committee, in Management of MDR-TB: A Field Guide: A Companion Document to Guidelines for Programmatic Management of Drug-Resistant Tuberculosis: Integrated Management of Adolescent and Adult Illness (IMAI) [EB/OL]. [2009-01-27].https://www.who.int/publications/i/item/9789241547765.
[8] LEUNG CC, YEW WW, MOK TYW, et al.Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis[J]. Respirology, 2017,22(6): 1225-1232.
[9] 马瑛龙, 叶强, 杨正贵, 等. 肺结核患者服用吡嗪酰胺引起血尿酸水平变化58例分析[J]. 宁夏医学杂志, 2021,43(10): 921-923.
[10] 国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 国家代谢性疾病临床医学研究中心, 等. 结核病与糖尿病共病的治疗管理专家共识[J]. 中国防痨杂志, 2021, 43(1): 12-22.
[11] VAN INGEN J, AARNOUTSE RE, DONALD PR, et al.Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?[J]. Clin Infect Dis, 2011,52(9): e194-e199.
[12] SAKTIAWATI AMI, SUBRONTO YW.Influence of Diabetes Mellitus on the Development of Multi Drug Resistant-Tuberculosis in Yogyakarta[J]. Acta Med Indones, 2018, 50(1): 11-17.
[13] NIJLAND H M, RUSLAMI R, STALENHOEF JE, et al.Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes[J]. Clin Infect Dis, 2006,43(7): 848-854.
[14] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021,13(4): 315-409.
[15] SINGHAL A, JIE L, KUMAR P, et al. Metformin as adjunct antituberculosis therapy[J]. Sci Transl Med, 2014,6(263): 263ra159.
[16] TE BRAKE LHM, YUNIVITA V, LIVIA R, et al.Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients[J]. Clin Pharmacol Ther, 2019,105(3): 730-737.
[17] 谭运彩,袁媛, 杨双喜,等. 二甲双胍与2型糖尿病患者肺结核感染风险的倾向性评分匹配分析[J/CD]. 新发传染病电子杂志, 2021, 6(3): 202-205.
[18] ZHANG M, HE JQ.Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis[J]. Eur J Clin Pharmacol, 2020, 76(2): 149-159.
[19] KEWCHAROENWONG C, SAENWONGSA W, WILLCOCKS SJ, et al.Glibenclamide alters interleukin-8 and interleukin-1β of primary human monocytes from diabetes patients against Mycobacterium tuberculosis infection[J]. Tuberculosis (Edinb), 2020,123:101939.
[20] KEWCHAROENWONG C, PRABOWO SA, BANCROFT GJ, et al.Glibenclamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 Polarization[J]. Front Immunol, 2018,9:2109.
[21] RUSLAMI R, AARNOUTSE RE, ALISJAHBANA B, et al.Implications of the global increase of diabetes for tuberculosis control and patient care[J]. Trop Med Int Health, 2010,15(11): 1289-1299.
[22] KUMAR A, ALAM A, GROVER S, et al.Peptidyl-prolyl isomerase-B is involved in Mycobacterium tuberculosis biofilm formation and a generic target for drug repurposing-based intervention[J]. NPJ Biofilms Microbiomes, 2019,5(1): 3.
[23] HA J, LIM Y, KIM MK, et al.Comparison of the Effects of Various Antidiabetic Medication on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus[J]. Endocrinol Metab (Seoul), 2021,36(4): 895-903.
[24] CHEN HH, HSIEH MC, HO CW, et al.Effects of dipeptidyl peptidase-4 inhibitor treatment doses on tuberculosis in patients with diabetes: a long-term nationwide population-based cohort study[J]. Ann Palliat Med, 2020,9(5): 2817-2825.
[25] SARMA S, PALCU P.Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis[J]. Obesity (Silver Spring), 2022,30(11):2111-2121.